目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T4295 | Dehydrogenase | ||
(R)-GNE-140 (GNE-140) 是 LDHA 抑制剂,能够作用于 LDHA (IC50:3 nM) 和 LDHB (IC50:3 nM)。它的活性是 S 型异构体的 18 倍。 | |||
T1768 | Mitochondrial Metabolism Monocarboxylate transporter | ||
7ACC2 是单羧酸盐转运蛋白抑制剂,IC50为 11 nM。它还是线粒体丙酮酸转运的有效抑制剂,可抑制乳酸涌入,通过抑制乳酸通量来发挥抗癌作用。 | |||
T11546 | Dehydrogenase | ||
hDHODH-IN-1 是有效的人二氢乳清酸脱氢酶抑制剂, 显示出抗炎作用。 | |||
T3105 | Apoptosis Glucokinase Autophagy | ||
PFK158 是一种选择性的PFKFB3抑制剂,IC50值为 137 nM。它可减少癌细胞中葡萄糖的摄取,ATP 的产生,乳酸的释放,并诱导细胞凋亡和自噬。它还可以增强 Colistin 对细菌的抵抗力,具有广泛的抗肿瘤活性。 | |||
TN2252 | Dopamine Receptor | ||
Syrosingopine 是 MCT1和 MCT4双重抑制剂,对 MCT4 的效力高 60 倍,可防止乳酸和 H+ 流出。它是可口服抗高血压药物,联合二甲双胍具有研究癌症疾病的潜力。 | |||
T12438 | Dehydrogenase Parasite | ||
PfDHODH-IN-1 是 Leflunomide 活性代谢物的类似物,具有抗疟疾活性。它是恶性疟原虫二氢乳清酸脱氢酶抑制剂。 | |||
T7482 | GPR | ||
3-Chloro-5-hydroxybenzoic acid 是一种口服具有活力的乳酸受体GPR81选择性激动剂,对人 GPR81 的EC50为 16 μM。肥胖小鼠模型中,它表现出良好的体内脂肪分解作用。 | |||
T3175 | Dehydrogenase | ||
LDHA-IN-4 (AZ33) 是乳酸脱氢酶 A 选择性抑制剂,IC50=0.5 μM,Kd=0.093 μM。 | |||
T7964 | Others Dehydrogenase | ||
Isomalt (Palatinitol) 是无毒的、具有良好耐受性的多元醇和蛋白质稳定的赋形剂,在冷冻干燥过程中可适度稳定乳酸脱氢酶(LDH),并在储存期间表现更好。它传统上在食品工业中用作甜味剂,也在制药中用作压片赋形剂。 | |||
T5325 | Dehydrogenase Parasite | ||
Nifurtimox (BAY-A-2502) 是一种用于锥虫病的抗虫剂,可影响乳酸脱氢酶活性。它有潜力研究神经母细胞瘤细胞。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-04180 | PfLDH Protein, P. falciparum, Recombinant (His) | P. falciparum | E. coli | ||
Plasmodium falciparum lactate dehydrogenase (PfLDH) is a key enzyme for energy generation of malarial parasites and is considered to be a potential antimalarial target. The ability of PfLDH- or PfIDEh-based immuno-PCR assays to detect <1 parasite/microL suggests that improvements of bound antibody sensor technology may greatly increase the sensitivity of malaria rapid diagnostic tests. The PfLDH test could be used to detect failures and, therefore, to assess anti-malarial efficacy.
|
|||||
TMPY-04241 | LDHA Protein, Rat, Recombinant (His) | Rat | E. coli | ||
LDHA (Lactate Dehydrogenase A) is a Protein Coding gene. The protein encoded by this gene catalyzes the conversion of L-lactate and NAD to pyruvate and NADH in the final step of anaerobic glycolysis. LDHA, a key enzyme regulating aerobic glycolysis, belongs to the lactate dehydrogenase family and is overexpressed in many human cancers, and correlates with poor clinical outcomes. LDHA can promote the Warburg effect to produce lactate and Adenosine Triphosphate (ATP) in aerobic conditions, which contributes to oncogenesis metastasis and drug resistance in various cancers. Up-regulation of lactate dehydrogenase LDHA is a frequent event in human malignancies and relate to poor postoperative outcome. Diseases associated with LDHA include Fanconi-Bickel Syndrome and Myoglobinuria.
|
|||||
TMPY-00010 | LDHA Protein, Mouse, Recombinant (His) | Mouse | E. coli | ||
LDHA (Lactate Dehydrogenase A) is a Protein Coding gene. The protein encoded by this gene catalyzes the conversion of L-lactate and NAD to pyruvate and NADH in the final step of anaerobic glycolysis. LDHA, a key enzyme regulating aerobic glycolysis, belongs to the lactate dehydrogenase family and is overexpressed in many human cancers, and correlates with poor clinical outcomes. LDHA can promote the Warburg effect to produce lactate and Adenosine Triphosphate (ATP) in aerobic conditions, which contributes to oncogenesis metastasis and drug resistance in various cancers. Up-regulation of lactate dehydrogenase LDHA is a frequent event in human malignancies and relate to poor postoperative outcome. Diseases associated with LDHA include Fanconi-Bickel Syndrome and Myoglobinuria.
|
|||||
TMPJ-00797 | LDHB Protein, Human, Recombinant (His) | Human | E. coli | ||
L-Lactate Dehydrogenase B Chain (LDH-B) is a member of the lactate dehydrogenase family that consists of three members, LDH-A, LDH-B and LDH-C; members of this family function as powerful markers for germ cell tumors. LDH-B is an oxidoreductase that catalyzes the interconversion of pyruvate and lactate with concomitant interconversion of NADH and NAD+. It converts pyruvate to lactate when oxygen is absent or in short supply and it performs the reverse reaction during the Cori cycle in the liver. It is also called Hydroxybutyrate Dehydrogenase (HBD) due to its ability to catalyze the oxidation of hydroxybutyrate.
|
|||||
TMPH-03136 | L-lactate dehydrogenase Protein, Plasmodium berghei, Recombinant (His & Myc) | Plasmodium berghei | E. coli | ||
L-lactate dehydrogenase Protein, Plasmodium berghei, Recombinant (His & Myc) is expressed in E. coli.
|
|||||
TMPJ-00724 | LDHA Protein, Human, Recombinant (His) | Human | E. coli | ||
L-Lactate Dehydrogenase A Chain (LDHA) is an enzyme that catalyzes the conversion of L-lactate and NAD+ to pyruvate and NADH in the final step of anaerobic glycolysis. LDHA contains an N-terminal coenzyme binding region, a central catalytic site, and at least nine utilized Lys acetylation and two Tyr phosphorylation sites. LDHA belongs to the lactate dehydrogenase family, expressed predominantly in muscle tissue. LDHA mutations have been linked to exertional myoglobinuria.
|
|||||
TMPH-00693 | L-lactate dehydrogenase Protein, E. coli O9:H4, Recombinant (His) | E. coli | E. coli | ||
Catalyzes the conversion of L-lactate to pyruvate. Is coupled to the respiratory chain.
|
|||||
TMPY-04826 | LILRB5/CD85c Protein, Human, Recombinant (His) | Human | HEK293 | ||
A genetic variant in LILRB5 (leukocyte immunoglobulin-like receptor subfamily-B) (rs12975366: T > C: Asp247Gly) has been reported to be associated with lower creatine phosphokinase (CK) and lactate dehydrogenase (LDH) levels. Both biomarkers are released from injured muscle tissue, making this variant a potential candidate for susceptibility to muscle-related symptoms.
|
|||||
TMPH-01696 | SLC16A4 Protein, Human, Recombinant (His) | Human | E. coli | ||
Proton-linked monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate.
|
|||||
TMPY-05186 | LILRB5/CD85c Protein, Human, Recombinant (His), Biotinylated | Human | HEK293 | ||
A genetic variant in LILRB5 (leukocyte immunoglobulin-like receptor subfamily-B) (rs12975366: T > C: Asp247Gly) has been reported to be associated with lower creatine phosphokinase (CK) and lactate dehydrogenase (LDH) levels. Both biomarkers are released from injured muscle tissue, making this variant a potential candidate for susceptibility to muscle-related symptoms.
|
|||||
TMPY-06273 | LILRB5/CD85c Protein, Human, Recombinant (hFc) | Human | HEK293 | ||
A genetic variant in LILRB5 (leukocyte immunoglobulin-like receptor subfamily-B) (rs12975366: T > C: Asp247Gly) has been reported to be associated with lower creatine phosphokinase (CK) and lactate dehydrogenase (LDH) levels. Both biomarkers are released from injured muscle tissue, making this variant a potential candidate for susceptibility to muscle-related symptoms.
|
|||||
TMPH-01202 | D2HGDH Protein, Human, Recombinant (His & SUMO) | Human | E. coli | ||
Catalyzes the oxidation of D-2-hydroxyglutarate (D-2-HG) to alpha-ketoglutarate. Also catalyzes the oxidation of other D-2-hydroxyacids, such as D-malate (D-MAL) and D-lactate (D-LAC). Exhibits high activities towards D-2-HG and D-MAL but a very weak activity towards D-LAC.
|
|||||
TMPY-02288 | Glyoxalase II/HAGH Protein, Human, Recombinant (His) | Human | E. coli | ||
HAGH (Hydroxyacylglutathione Hydrolase) is a Protein Coding gene. 3 alternative splicing and alternative initiation of human isoforms have been reported. The enzyme encoded by this gene is classified as a thioesterase and is responsible for the hydrolysis of S-lactoyl-glutathione to reduced glutathione and D-lactate. HAGH belongs to the Metallo-beta-lactamase superfamily. HAGH is widely expressed in the kidney, liver, and other tissues. Diseases associated with HAGH include Hydroxyacyl Glutathione Hydrolase Deficiency. Among its related pathways are Pyruvate metabolism and Citric Acid (TCA) cycle and Metabolism. The human and rodent forms of glyoxalase II (HAGH) can readily be separated by starch gel electrophoretic procedures.
|
|||||
TMPH-01860 | PCK1 Protein, Human, Recombinant (His) | Human | E. coli | ||
Cytosolic phosphoenolpyruvate carboxykinase that catalyzes the reversible decarboxylation and phosphorylation of oxaloacetate (OAA) and acts as the rate-limiting enzyme in gluconeogenesis. Regulates cataplerosis and anaplerosis, the processes that control the levels of metabolic intermediates in the citric acid cycle. At low glucose levels, it catalyzes the cataplerotic conversion of oxaloacetate to phosphoenolpyruvate (PEP), the rate-limiting step in the metabolic pathway that produces glucose from lactate and other precursors derived from the citric acid cycle. At high glucose levels, it catalyzes the anaplerotic conversion of phosphoenolpyruvate to oxaloacetate. Acts as a regulator of formation and maintenance of memory CD8(+) T-cells: up-regulated in these cells, where it generates phosphoenolpyruvate, via gluconeogenesis. The resultant phosphoenolpyruvate flows to glycogen and pentose phosphate pathway, which is essential for memory CD8(+) T-cells homeostasis. In addition to the phosphoenolpyruvate carboxykinase activity, also acts as a protein kinase when phosphorylated at Ser-90: phosphorylation at Ser-90 by AKT1 reduces the binding affinity to oxaloacetate and promotes an atypical serine protein kinase activity using GTP as donor. The protein kinase activity regulates lipogenesis: upon phosphorylation at Ser-90, translocates to the endoplasmic reticulum and catalyzes phosphorylation of INSIG proteins (INSIG1 and INSIG2), thereby disrupting the interaction between INSIG proteins and SCAP and promoting nuclear translocation of SREBP proteins (SREBF1/SREBP1 or SREBF2/SREBP2) and subsequent transcription of downstream lipogenesis-related genes.
|